Robert-Guroff Marjorie
National Institutes of Health, National Cancer Institute, Vaccine Branch, 41 Medlars Drive, Building 41, Room D804, Bethesda, MD 20892-5065, United States.
Curr Opin Biotechnol. 2007 Dec;18(6):546-56. doi: 10.1016/j.copbio.2007.10.010. Epub 2007 Dec 11.
Viral vectors provide a convenient means to deliver vaccine antigens to select target cells or tissues. A broad spectrum of replicating and non-replicating vectors is available. An appropriate choice for select applications will depend on the biology of the infectious agent targeted, as well as factors such as whether the vaccine is intended to prevent infection or boost immunity in already infected individuals, prior exposure of the target population to the vector, safety, and the number and size of gene inserts needed. Here several viral vectors under development as HIV/AIDS vaccines are reviewed. A vaccine strategy based on initial priming with a replicating vector to enlist the innate immune system, target mucosal inductive sites, and prime both cellular and humoral systemic and mucosal immune responses is proposed. Subsequently, boosting with a replicating or non-replicating vector and/or protein subunits could lead to induction of necessary levels of protective immunity.
病毒载体为将疫苗抗原递送至特定靶细胞或组织提供了一种便捷的手段。有多种复制型和非复制型载体可供选择。针对特定应用的合适选择将取决于所靶向的感染因子的生物学特性,以及诸如疫苗是旨在预防感染还是增强已感染个体的免疫力、靶人群先前是否接触过该载体、安全性以及所需基因插入片段的数量和大小等因素。本文综述了几种正在研发的作为HIV/艾滋病疫苗的病毒载体。提出了一种疫苗策略,即先用复制型载体进行初次免疫,以动员先天免疫系统、靶向黏膜诱导部位,并启动细胞和体液的全身及黏膜免疫反应。随后,用复制型或非复制型载体和/或蛋白质亚基进行加强免疫,可能会诱导产生必要水平的保护性免疫。